AbbVie (ABBV) Stock Forecast & Price Target

AbbVie has demonstrated strong financial performance, as evidenced by its 1Q 2025 sales of $13.34 billion, surpassing both expectations and consensus forecasts, driven primarily by robust sales from key immunology and oncology products like Skyrizi and Rinvoq. The company has also provided an upward revision in its FY 2025 guidance, increasing revenue expectations by $700 million to approximately $59.7 billion and raising non-GAAP EPS guidance to a range of $12.09 to $12.29, reflecting sustained growth across important segments. Additionally, AbbVie's strategic acquisitions, including Cerevel and ImmunoGen, further bolster its portfolio, positioning the company favorably for future growth in neuroscience and oncology.

The financial outlook for AbbVie is overshadowed by several fundamental risks, including potential disappointing commercial performance of key products like Skyrizi, Rinvoq, and Botox, which could hinder revenue growth. Additionally, the anticipated erosion of Humira's market share due to biosimilar competition beginning in 2025 and competitive pressures on the oncology portfolio pose significant challenges to long-term profitability. Macroeconomic factors, particularly those affecting consumer discretionary spending and potential regulatory impacts, could further undermine AbbVie's revenue generation and stability in its aesthetics business, which has become increasingly vulnerable.